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Summary — A recent editorial is discussed, which implied that animal-based developmental and reproductive toxicology tests will continue to be crucial, that the thalidomide disaster could have been prevented
by more animal testing, and that tests on juvenile animals would help to protect children (as developing
adults) from the adverse effects of pharmaceuticals. It is argued that animal tests in these scientific areas
do not provide reliable data that are predictive for human responses and, even if they did, the tests are too
expensive and time-consuming for application to the very large number of substances that need to be
tested. It is estimated there are already more than 100,000 man-made chemicals to which humans may be
exposed on a regular basis, and it is therefore widely accepted that in vivo developmental toxicology could
not possibly be used to assess all new and existing chemical substances, due to the scale of its demand
upon time and resources. It is therefore imperative that alternatives such as those outlined above are
embraced, further developed, accepted and used — as a matter of urgency.
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Introduction
A recent Guest Editorial in Lab Animal Europe,
“Developmental and reproductive toxicity testing: a
potted history” (1) affirmed that “the ultimate goal
of developmental and reproductive toxicology testing is to provide data for risk assessment… to protect our future generations.” While this is not in
doubt, the article implied that this would involve a
continued dependence on animal-based tests.
However, this laudable goal cannot be achieved
via such means. There is ample evidence to show
that this ‘data for risk assessment,’ when obtained
from animal tests, is not suitable for this purpose
— it neither permits confident human-risk assessment, nor serves to protect our future generations.

Reliability and Concordance of
Animal Data
The data presented here summarise some of the
salient points of a comprehensive, systematic and
non-selective study completed in 2005 (2), which
examined the developmental toxicity results for
almost 1400 substances in 12 different species, by
using several databases and reference texts.
Historical data — across twelve species
An analysis of the responses of up to 12 animal
species to 11 groups of known human teratogens

(grouped by drug class/chemical nature) revealed
significant discordance: the positive predictability
ranged from 75% for the hamster, down to 40% for
the rabbit, which also exhibited a false-negative
rate of 40%. The mean positive predictability rate
in the six species most frequently used historically
(mouse, rat, rabbit, hamster, primate, dog) was
less than 55%, and the number of equivocal results
remained high at just under 25%.
Furthermore, there were 139 animal results
across different species for 35 individual substances positively linked with human teratogenicity. Just over half (56%) of the animal results were
positive. This poor predictability was underlined
by a US Food and Drug Administration (FDA)
report which detailed the responses of the mouse,
rat, rabbit, hamster and monkey to 38 known
human teratogens, in which the mean percentage
of correct positives was only 60% (3). This report
also analysed 165 compounds known to be non-teratogenic in humans, for which the mean negative
predictive value for these five species was 54%.
Contemporary data — for two species, rat
and rabbit
For groups of known human teratogens, results from
tests in the rat correlated with human classifications
in 64% of cases; for the rabbit, this correlation was
40%. When this analysis was focused on 35 individual substances known to be associated with human
teratogenesis, the positive predictability for the rat

Comments

719

was 61%, with 29% of the results falsely negative.
The rabbit was positively predictive in 41% of cases,
but produced false-negative results for 56% of substances. A small number of equivocal results were
obtained in both these species (Table 1, depicting our
analysis of results and classifications contained in
Schardein’s book [4]).
The performances of the rat and rabbit in teratology tests were further elucidated by examining
the results for the 20 chemicals used in the
ECVAM validation studies on three non-animal
alternative methods for developmental toxicology
(Table 2). Nine of these substances had a human
risk classification with which to compare the rat
and rabbit results:
— four ‘unlikely’ human teratogens produced two
negative, one equivocal and one positive result
in the rat, and 3 negative and 1 positive result
in the rabbit.
— three ‘minimal-to-small risk’ human teratogens
produced three positive results in the rat, and
one positive in the rabbit (the other two were
not tested).

— two ‘moderate-to-high risk’ human teratogens
produced positive results in both the rat and the
rabbit.
Based on these data, it can be argued that the tests
in the rat and the rabbit are not sufficiently predictive to justify their use, and that the high rate
of false-negatives also raises concern over their
human relevance and applicability. This lack of
predictive power is also underlined by the statistic
that, of 3301 substances tested prior to 1993, 37%
were classified as definitely, probably or possibly
teratogenic in animals, but fewer than 2.3% of
these substances were linked to human birth
defects. (4).

Summary and Conclusions
The predictive nature of animal
developmental toxicity tests
Contrary to Moxon’s assertions that animal-based
developmental toxicology provides valuable data to

Table 1: The results from rat and rabbit teratology tests for known human teratogens

Rat
Rabbit

Total no. of
substances

+

+/–

–

True
positive (%)

False
negative (%)

31
27

19*
11

3
1

9
15

61%
41%

29%
56%

The total numbers of results in the rat and rabbit for the 35 known human teratogens (categorised by
Schardein [4]) are shown, followed by the number of positive (+), equivocal (+/–) and negative (–) conclusions. The final two columns reveal the percentages of rat and rabbit results that represented True Positives
and False Negatives for these substances. * = one of these results was strain-dependent.

Table 2: The results from rat and rabbit teratology tests for nine chemicals used in ECVAM
validation studies on non-animal alternative methods that had human risk
classifications
Human teratogenic potential
Unlikely

Rat
Rabbit

Minimal-to-small risk

+

+/–

–

+

1
1

1

2
3

3
1

+/–

–

Moderate-to-high risk
+

+/–

–

2
2

The results for those nine substances for the rat and the rabbit, where they existed, are provided for chemicals classified as posing ‘unlikely’, ‘minimal-to-small’ and ‘moderate-to-high’ human teratogenic risks.
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enable reliable human risk assessment, the examination of substantive data from decades of
animal-based teratology revealed significant variability in positive and negative predictability, and
high rates of false-positives, false-negatives and
equivocal outcomes across twelve species. These
tests are therefore not suitable for their intended
purpose.
Further, while accepting the inherent scientific
and technical challenges involved, Moxon implies a
necessary role for juvenile animals in assessing the
safety of pharmaceuticals for children, based on an
acknowledgement of important differences
between children and adult humans and their susceptibilities to the effects of pharmaceuticals. It
may be true that potential adverse events cannot
be assessed ethically and safely in paediatric clinical trials, and that therefore some form of effective
preclinical investigations must be conducted.
However, one must be sceptical that animal teratology studies of any kind are fit for this purpose,
given the statistics presented here and their illustration of the lack of predictability of this
approach.
Alternative approaches to developmental
toxicity tests
Fortunately, a number of alternatives to animal
testing exist or are in the course development, with
the potential to improve the field of developmental
toxicology in terms of time, cost and, most importantly, improved human predictability. Thus, it is
anticipated that alternatives to the current animal-based methods will greatly enhance the number of substances that can be evaluated for
potential developmental toxicity, at lower cost and
in a shorter time frame. It is estimated there are
already more than 100,000 man-made chemicals to
which humans may be exposed on a regular basis
(5), and it is therefore generally accepted that in
vivo developmental toxicology could not possibly be
used to assess all the new and existing chemical
substances due to the scale of its demands upon
time and resources (6).
Computer-based systems, such as expert systems and structure–activity relationship (SAR)
analyses, and physiologically based pharmacokinetic modelling (PBPK), have already been responsible for the elimination of many animal tests in
the pre-screening of candidate drug compounds.
The recently established US Environmental Protection Agency (EPA) ToxCast™ programme
employs the computational modelling of highthroughput screening data to assist in prediction of
the potential toxicities of chemicals to humans,
incorporating reproductive endpoints, as well as
other endpoints, including a variety of biochemical
and developmental assays (7).
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The use of lower organisms, embryo stages and
cell, tissue and organ cultures, was endorsed as
scientifically validated in 2001. The Embryonic
Stem Cell Test, for instance, uses two permanent
murine cell lines to screen for teratogenic potential
(8–12), and has scored highly on predictability,
precision and accuracy in independent validation
studies. It is already considered to be more reproducible, provide easier end-points, present no problems with respect to ‘route of exposure,’ placental
transfer and metabolic differences, and is devoid of
the confounding factors associated with animal
tests, such as intra-species variability, environmental factors, differences in metabolism, placental and other anatomies, absorption, sensitivity,
metabolic activation, routes of administration,
dose levels and strategies. It provides a means to
establish vital mechanistic models of teratogenic
action, via gene expression analysis, for example,
which will decrease the cost and increase the number of chemicals evaluated for developmental toxicity, could reduce the human impact of the
false-positive and false-negative results generated
by animal models, and could also greatly reduce
the numbers of animals used (2, 13). As human cell
culture and other technologies improve, new protocols will evolve, that will enable an even closer in
vitro approximation of in vivo human teratogenesis
(14).
In addition, risk assessment can be aided by better information and data comparison and data
sharing, and also by valuable human studies and
birth-defect registries, which have identified many
important human teratogens (2, 15).
In conclusion, the article by Moxon (1), which
implied that animal-based developmental and
reproductive toxicology tests will continue to be
crucial, that the thalidomide disaster could have
been prevented by more animal testing, and that
tests on juvenile animals would help to protect
children (as developing adults) from the adverse
effects of pharmaceuticals, has little or no scientific basis. Animal tests in these scientific areas do
not provide reliable data that are predictive for
human responses and, even if they did, the tests
are too expensive and time-consuming for application to the very large number of substances that
need to be tested. It is therefore imperative that
alternatives such as those outlined above are
embraced, further developed, accepted and used —
as a matter of urgency.
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